UK Cannabis Clinical Trials: Active Studies

UK best UK cannabis clinicsal Trials 2025: Active Studies

Clinical trials investigating the safety and efficacy of medical cannabis continue to expand across the United Kingdom in 2025. Following the rescheduling of cannabis as a Schedule 2 controlled drug in November 2018, which enabled medical research to proceed, the landscape of cannabis-based clinical investigations has matured. This article outlines the current state of active clinical trials, what they mean for patients, and how they contribute to the evidence base for medical cannabis UK treatment pathways.

The Current Research Landscape in 2025

As of 2025, there are an estimated 15-25 registered clinical trials across the UK investigating cannabis-based medicines for various conditions. These studies range from early-phase safety evaluations to larger Phase III trials examining therapeutic efficacy. The Medicines and Healthcare products Regulatory Agency (MHRA) maintains oversight of these investigations, ensuring they meet rigorous safety and ethical standards.

The UK research environment has been shaped by several key initiatives. The Medical Cannabis Registry, established to collect real-world evidence from patients accessing cannabis-based medicines through NHS channels and private prescription, continues to generate valuable data. Additionally, specialist centres have established dedicated research units, with notable activity at leading hospital trusts and private research facilities.

Estimates suggest that between 2019 and 2025, over 500 patients have participated in structured clinical trials examining cannabis-based treatments in the UK, with a further estimated 5,000-10,000 patients contributing data through real-world evidence collection programmes. This growing evidence base has been crucial in shaping clinical understanding.

Conditions Under Active Investigation

Current UK clinical trials are examining cannabis-based medicines across several therapeutic areas. Epilepsy remains a significant focus, following the earlier licensing of Epidyolex (cannabidiol) by the MHRA. Ongoing studies explore combination therapies and patient subgroups who may benefit most from cannabinoid treatments.

Chronic pain conditions, including neuropathic pain and cancer-related pain, feature prominently in the trial portfolio. These investigations aim to establish optimal dosing strategies and identify patient characteristics predictive of positive response.

Emerging research areas in 2025 include multiple sclerosis-related spasticity, post-traumatic stress disorder (PTSD), and chemotherapy-induced nausea and vomiting (CINV). Some trials are also examining cannabis-based medicines for treatment-resistant anxiety disorders, though this remains a developing area with limited current evidence.

Several trials are investigating products with differing cannabinoid profiles—including high-THC, high-CBD, and balanced THC:CBD formulations—to understand how different cannabinoid ratios affect therapeutic outcomes and adverse effects.

Access to Clinical Trials for UK Patients

Patients seeking to participate in active clinical trials should be aware that eligibility criteria are typically strict and condition-specific. Trial participation is generally coordinated through specialist centres, hospital trusts, and licensed research facilities. Interested patients should discuss with their healthcare provider whether they might be suitable candidates for any ongoing studies.

The NHS refers some eligible patients to trials, particularly where conventional treatments have proven ineffective. However, many trials also operate privately, and patients may need to meet costs if not accessed through the NHS pathway. Understanding the differences between NHS-regulated access and UK cannabis law compliance for private prescribing is important for patients considering trial participation.

Trial participation offers potential benefits, including access to cannabis-based medicines while contributing to the evidence base. However, participants must understand that experimental treatments carry inherent uncertainties, and participation requires informed consent and ongoing monitoring.

Regulatory Framework and Trial Approval

All clinical trials investigating cannabis-based medicines in the UK must obtain approval from the MHRA and navigate Research Ethics Committee review. This rigorous approval process ensures trials meet international standards for safety, scientific validity, and ethical conduct.

The MHRA operates under a regulatory framework that distinguishes between cannabis-based medicines (defined as products containing cannabinoids in a pharmaceutical form) and unlicensed cannabis products. Licensed medicines like Epidyolex and Sativex have undergone full pharmaceutical approval, whilst many clinical trials are evaluating other formulations seeking eventual licensing.

Trial data is typically submitted to the MHRA and relevant scientific bodies. The National Institute for Health and Care Excellence (NICE) considers evidence from trials when updating guidance on cannabis-based medicines. As of 2025, NICE continues to recommend that cannabis-based medicines should only be considered when other treatment options have been ineffective, though new evidence may influence future recommendations.

Contributing to Evidence and Future Clinical Practice

Clinical trials conducted in 2025 and beyond will shape how medical cannabis UK is integrated into mainstream NHS practice. Currently, evidence remains limited for many conditions beyond epilepsy, which delays wider NHS availability. Well-designed, properly powered trials are essential for establishing clinical utility and cost-effectiveness.

The data emerging from current trials will inform training for healthcare professionals, protocols for patient selection, and standardised dosing recommendations. Estimated timelines suggest that results from major ongoing trials may become available between 2025 and 2027, potentially influencing NICE guidance updates and NHS commissioning decisions.

Patients should recognise that participating in clinical research, whilst carrying some uncertainties, contributes to building the evidence base that will eventually benefit broader patient populations. This is particularly valuable in areas where cannabis-based medicines represent a genuinely novel therapeutic approach.

Frequently Asked Questions

How can I find information about current clinical trials recruiting in my area?

Your GP or specialist can provide information about trials they may refer you to. The MHRA’s website contains a searchable database of approved clinical trials. You can also contact specialist best UK cannabis clinics directly, as they maintain awareness of relevant ongoing studies and may assess your eligibility.

If I participate in a clinical trial, will I be able to continue cannabis-based treatment afterwards?

This depends on the trial protocol and your individual circumstances. Some trials include provisions for continued access post-trial if the treatment proves beneficial, whilst others do not. You should clarify this with the research team before enrolling. Access outside trials remains governed by current NHS commissioning arrangements and UK cannabis law regulations.

Are clinical trials the only way to access medical cannabis legally in the UK?

No. Patients can access cannabis-based medicines through NHS prescription (where criteria are met and commissioning permits), via private prescription from registered medical professionals, or through approved clinical trials. Each pathway has different eligibility criteria and costs. Trials represent one option within the broader landscape of legal medical cannabis access.